Arockiasamy Arulandu

About

Group Leader, Structural Biology Group
International Centre for Genetic Engineering and Biotechnology
Aruna Asaf Ali Marg, New Delhi-110067. India

Our research is dedicated to early-stage drug discovery, specifically focusing on the development of structure-based therapeutics for Atherosclerotic Cardiovascular Disease (ASCVD) and cancer, targeting oxidized low-density lipoprotein (oxLDL) receptor LOX-1, and CLIC1, respectively. We use cutting-edge CADD techniques to identify, design, and optimize potential lead candidates for IND development. These candidates undergo extensive and rigorous in vitro validation through biochemical, biophysical, and cell-based assays. Promising candidates are further evaluated in in vivo mouse models to assess their safety, efficacy, and pharmacokinetic characteristics, and move them closer to filing an IND. Our main objective is to find and create tailored treatments that can dramatically lower death rates and enhance the quality of life for those afflicted with these devastating diseases.

Employment

• International Centre for Genetic Engineering and Biotechnology Group Leader
  2024 - Present
• International Centre for Genetic Engineering and Biotechnology New Delhi Group Leader
  2016 - 2024
• University of Arkansas for Medical Sciences Visiting Associate Professor
  2016 - 2016
• University of Arkansas for Medical Sciences Visiting Associate Professor
  2015 - 2015
• International Centre For Genetic Engineering and Biotechnology Staff Research Scientist
  2006 - 2015
• Texas A&M University Assistant Research Scientist
  2003 - 2006
• Texas A&M University Post-Doctoral Fellow
  2001 - 2003
• University of Illinois at Chicago Post-doctoral Fellow
  2000 - 2001

Education

• Madurai Kamaraj University PhD in Structural Biology and Biophysics
  1994 - 2000
• Madurai Kamaraj University MSc in Biology
  1991 - 1993
• Bharathidasan University BSc in Chemistry
  1989 - 1991

Projects & Funding

Projects & funding information is unavailable.

Publications (26)

• Loop of fate: structural and mechanistic insights into hnRNPA1 binding to the hepatitis C virus RNA
  RNA 2026 DOI: 10.1261/rna.080770.125
  +Save
• A cryptic-site ligand stabilizes a non-canonical interface and blocks membrane insertion of the chloride intracellular channel CLIC1.
  The Journal of biological chemistry 2026 DOI: 10.1016/j.jbc.2026.113113
  +Save
• Humanized recombinant immunotoxin targeting hCG demonstrates therapeutic potential for advanced stage difficult to treat cancers
  Journal of Drug Targeting 2025 DOI: 10.1080/1061186X.2024.2416247
  +Save
• Oxidized LDL receptors: a recent update
  Current Opinion in Lipidology 2023 DOI: 10.1097/mol.0000000000000884
  +Save
• Biochemical and structural characterization of a robust and thermostable ascorbate recycling monodehydroascorbate reductase (MDHAR) from stress adapted pearl millet
  Biochemical and Biophysical Research Communications 2023 DOI: 10.1016/j.bbrc.2023.04.034
  +Save
• Plant dehydroascorbate reductase moonlights as membrane integrated ion channel
  Archives of Biochemistry and Biophysics 2023 DOI: 10.1016/j.abb.2023.109603
  +Save
• Exploring the druggability of oxidized low-density lipoprotein (ox-LDL) receptor, LOX-1, a proatherogenic drug target involved in atherosclerosis
  Biochemical and Biophysical Research Communications 2022 DOI: 10.1016/j.bbrc.2022.07.036
  +Save
• SWEET11 and SWEET12 transporters function in tandem to modulate sugar flux in Arabidopsis: An account of the underlying unique structure–function relationship
  2022 DOI: 10.1101/2022.03.26.485957
  +Save
• Comparative kinetic analysis of ascorbate (Vitamin-C) recycling dehydroascorbate reductases from plants and humans
  Biochemical and Biophysical Research Communications 2022 DOI: 10.1016/j.bbrc.2021.12.103
  +Save
• Dual avatars of E. coligrxB encoded Glutaredoxin 2 perform ascorbate recycling and ion channel activities
  [] 2021 DOI: 10.1101/2021.08.28.458008
  +Save